PRF Technologies Ltd. PRFX
PRF Technologies Ltd. (Nasdaq: PRFX) is an ophthalmology drug developer. Its lead program, OcuRing-K (ketorolac sustained-release intraocular ring; LayerBio), is in Phase 1 for Post-cataract-surgery inflammation and pain. Its next catalyst on record is OcuRing-K: LayerBio expects to start patient enrollment in the planned U.S. multi-center Phase 2 trial of OcuRing-K before year-end 2026. (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: OcuRing-K — LayerBio expects to start patient enrollment in the planned U.S. multi-center Phase 2 trial of OcuRing-K before year-end 2026. (2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| PRF-110 (extended-release ropivacaine) | Post-operative pain (bunionectomy) | small molecule | Phase 3 |
| OcuRing-K | Post-cataract-surgery inflammation and pain | device-combination | Phase 1 |
Recent results and decisions
- Oct 23, 2026positive PRF-110 demonstrated sustained 72-hour analgesic activity comparable to an approved extended-release product in preclinical head-to-head study.
In a head-to-head preclinical study, PRF-110 demonstrated sustained 72-hour analgesic activity comparable to an approved, commercially available extended-release product, using a ropivacaine-only, NSAID-free formulation.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 ophthalmology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.